Literature DB >> 773395

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

H B Hewitt, E R Blake, A S Walder.   

Abstract

Extensive experience with isotransplants of 27 different tumours (leukaemias, sarcomata, carcinomata), all of strictly spontaneous origin in laboratory bred mice of low cancer strains CBA/Ht and WHT/Ht, has revealed no evidence of tumour immunogenicity. Of approximately 20,000 maintenance transplants, none failed and none regressed; of almost 10,000 carefully observed tumours arising from small or minimal inocula of tumour cells, none spontaneously regressed. The number of injected viable tumour cells required to give a 50% probability of successful transplantation (the TD50) ranged from approximately 1 cell to greater than 10,000 cells among the 27 tumours; high TD50 values, which were dramatically reduced by various procedures having no immunological significance, did not signify active "resistance" of the hosts. In the case of all of 7 randomly selected tumours, prior "immunization" of recipients with homologous lethally irradiated cells increased their tumour receptivity. Several experiments using various tumours failed to give evidence that immunity could be non-specifically induced or that a massive preponderance of lymphocytes from specifically sensitized mice could inhibit tumour transplantation or growth in vivo; no trace of "resistance" to tumour was adopted by isogeneic recipients of lymphocytes from regional nodes of tumour bearers. A limited review of the recent literature on tumour immunity shows that practically all the animal data presented in support of a general theory of tumour immunogenicity or to provide a basis for active clinical immunotherapy have been obtained from transplanted tumour systems which entail artefactual immunity associated with viral or chemical induction of the tumours or their allogeneic transplantation. It is suggested that isotransplants of spontaneously arising tumours are the only appropriate models of human cancer and that any genuine rapport between the animal laboratory and the clinic requires their exclusive use.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773395      PMCID: PMC2024987          DOI: 10.1038/bjc.1976.37

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  BCG immunotherapy of rat tumors of defined immunogenicity.

Authors:  R W Baldwin; M V Pimm
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

2.  Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.

Authors:  R L Simmons; A Rios
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

3.  Immune suppression and carcinogenesis in hamsters during topical application of 7,12-dimethylbenz(a)anthracene.

Authors:  A K Szakal; M G Hanna
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

4.  Combined chemoimmunostimulation therapy against murine leukemia.

Authors:  J W Pearson; G R Pearson; W T Gibson; J C Chermann; M A Chirigos
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

5.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

6.  Role of the regional lymph nodes in the cure of a murine lymphosarcoma.

Authors:  C A Perez; C C Stewart; L A Palmer-Hanes; W E Powers
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

7.  Cellular radiosensitivity and tumor curability.

Authors:  W E Powers; L A Palmer; L J Tolmach
Journal:  Natl Cancer Inst Monogr       Date:  1967-02

8.  Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.

Authors:  G A Currie
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640

9.  Enhancement of syngeneic murine tumour transplantability by whole body irradiation--a non-immunological phenomenon.

Authors:  L J Peters
Journal:  Br J Cancer       Date:  1975-03       Impact factor: 7.640

10.  Biological effects of Corynebacterium parvum. 3. Amplification of resistance and impairment of active immunity to murine tumours.

Authors:  S E Smith; M T Scott
Journal:  Br J Cancer       Date:  1972-10       Impact factor: 7.640

View more
  117 in total

Review 1.  Immune recognition of self in immunity against cancer.

Authors:  Alan N Houghton; José A Guevara-Patiño
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 2.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 4.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

6.  Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Authors:  J H Sampson; G E Archer; D M Ashley; H E Fuchs; L P Hale; G Dranoff; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.

Authors:  A Van Pel; M Georlette; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

Review 8.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 9.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

10.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.